Axiogenesis Earns U.S. Patent With In Vitro Drug Discovery Assay for Hypertrophic Cardiomyopathy
12/4/2012 10:52:10 AM
COLOGNE, Germany--(BUSINESS WIRE)--The USPTO approved a patent for Axiogenesis AG for the invention of its in vitro assay to screen pharmaceutical drug candidates for effectiveness and safety in treating Hypertrophic Cardiomyopathy (HCM). The assay, which has previously received patents in Europe and Japan, is based on induced pluripotent stem (iPS) cell technology. Axiogenesis has developed the ability to induce HCM in iPS cell-derived cardiomyocytes, creating an in vitro model of the disease that can be used to evaluate drug candidates and molecular targets.